FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579208110> ?p ?o ?g. }

• W2579208110 abstract "Abstract The apoptotic mode of cell death is a major regulatory process in all complex organisms. The slow accumulation of malignant cells in chronic lymphocytic leukemia (CLL) suggests that this disease is caused by a defect in apoptosis regulation. Apoptosis, defined as a programmed cell death, is executed through activity of caspases, cysteine proteases which are regulated by a number of pro- and anti-apoptotic proteins. One of such checkpoints is a control of caspase activation by the family of inhibitor of apoptosis proteins (IAPs). So far eight IAP proteins have been identified in human. They were XIAP, cIAP1, cIAP2, ILP-2, NAIP, survivin and BRUCE/Apollon. Moreover, an important role in the regulation of apoptosis play also three proteins which bind to IAPs and inhibit their activity, such as Smac/DIABLO, HtrA2/Omi and XAF1. Until recently IAPs and their antagonists were poorly researched in CLL. The majority of them were even not investigated in this disease yet. The primary aim of the study was to perform a complex analysis of expression of the IAPs family proteins and their antagonists in leukemic cells (ex vivo) in untreated CLL patients in comparison to the healthy controls. In this study we have also aimed to assess differences in expression of these proteins between patients with stable(SD) and progressive disease (PD). We tried to establish a potential prognostic significance of the IAPs expression and to investigate their correlation with the clinical course of the disease. The last aim was to analyze the expression of these proteins in the cell culture (in vitro settings) in response to the drugs routinely used in CLL. One hundred untreated patients with CLL were included in the study. Patients were divided into two groups: with SD (n=52) and PD (n=48). Twenty seven healthy donors served as a control group. Expression of IAPs and their inhibitors were investigated by flow cytometry, after careful comparative studies by Western blot and fluorescence microscopy. Protein expression was assessed on the basis of the mean fluorescence intensity (MFI). Results were compared with several disease-related parameters, such as clinical stage according to Rai, lymphocyte count, ZAP-70 and CD38 expression or serum beta-2-microglobulin concentration. The secondary endpoint of the study was to compare the results with the outcome of examined patients. Our study revealed significantly higher expression of cIAP1 (median MFI level: 81.1 vs 8.2; p=0.000001) and cIAP2 (median MFI level: 313.5 vs 146.8; p=0.014) and lower expression of IAP-antagonist - Smac/DIABLO (median MFI level: 147.9 vs 301.3; p=0.010) in the group of untreated CLL patients in comparison to the control group. Furthermore, patients with PD showed significantly higher expression of all analyzed IAPs compared with those with SD. Median MFI level for cIAP1 were: 131.2 vs 60.1; p=0.002, for cIAP2: 434.3 vs 301.5; p=0.026, for XIAP: 463.7 vs 225.4; p=0.002 and for survivin: 119.6 vs 38.6; p=0.00006. We also found a positive correlation between all examined protein’s expression and clinical stage according to Rai and high lymphocytosis, but only XIAP correlated with beta-2-microglobulin concentration (p=0.017). Moreover the study showed that simultaneous expression of two or more IAPs is associated with shorter overall survival. Additionally, analyzing the expression of IAPs and their antagonists in the cell cultures (in vitro) in response to cytotoxic drugs (Cladribine, Fludarabine, Mafosfamide) we observed significantly lower level of cIAP1, cIAP2 and XIAP as well as a higher level of proapoptotic Smac/DLABLO in comparison to the control, cytostatic-free cultures. In conclusion, CLL cells are characterized by overexpression of cIAP1 and cIAP2 and downregulation of Smac/DIABLO. The anti-apoptotic pattern of these apoptosis-regulating proteins expression may be responsible for pathological accumulation of malignant cells in CLL. Moreover, expression of all IAP proteins is significantly elevated in patients with PD, what indicates a role of inhibited proclivity of CLL cells to undergo spontaneous apoptosis in the disease progression. Importantly, the co-expression of two or more IAP proteins in tumor cell seems to be unfavorable prognostic factor in CLL patients. Thus, all those data suggest that IAPs/IAP-antagonists system plays an important role in the biology of CLL and further studies to confirm their prognostic usefulness are warranted." @default.
• W2579208110 created "2017-01-26" @default.
• W2579208110 creator A5026532443 @default.
• W2579208110 creator A5039221511 @default.
• W2579208110 creator A5060741746 @default.
• W2579208110 creator A5069332579 @default.
• W2579208110 date "2008-11-16" @default.
• W2579208110 modified "2023-10-18" @default.
• W2579208110 title "Expression and Prognostic Significance of the Inhibitor of Apoptosis Protein (IAPs) Family and Its Antagonists in Chronic Lymphocytic Leukemia" @default.
• W2579208110 doi "https://doi.org/10.1182/blood.v112.11.360.360" @default.
• W2579208110 hasPublicationYear "2008" @default.
• W2579208110 type Work @default.
• W2579208110 sameAs 2579208110 @default.
• W2579208110 citedByCount "0" @default.
• W2579208110 crossrefType "journal-article" @default.
• W2579208110 hasAuthorship W2579208110A5026532443 @default.
• W2579208110 hasAuthorship W2579208110A5039221511 @default.
• W2579208110 hasAuthorship W2579208110A5060741746 @default.
• W2579208110 hasAuthorship W2579208110A5069332579 @default.
• W2579208110 hasConcept C149150037 @default.
• W2579208110 hasConcept C181199279 @default.
• W2579208110 hasConcept C182220744 @default.
• W2579208110 hasConcept C190283241 @default.
• W2579208110 hasConcept C203014093 @default.
• W2579208110 hasConcept C2775975398 @default.
• W2579208110 hasConcept C2777408456 @default.
• W2579208110 hasConcept C2777938653 @default.
• W2579208110 hasConcept C2778461978 @default.
• W2579208110 hasConcept C31573885 @default.
• W2579208110 hasConcept C33195913 @default.
• W2579208110 hasConcept C502942594 @default.
• W2579208110 hasConcept C55493867 @default.
• W2579208110 hasConcept C86803240 @default.
• W2579208110 hasConcept C95444343 @default.
• W2579208110 hasConcept C98424977 @default.
• W2579208110 hasConceptScore W2579208110C149150037 @default.
• W2579208110 hasConceptScore W2579208110C181199279 @default.
• W2579208110 hasConceptScore W2579208110C182220744 @default.
• W2579208110 hasConceptScore W2579208110C190283241 @default.
• W2579208110 hasConceptScore W2579208110C203014093 @default.
• W2579208110 hasConceptScore W2579208110C2775975398 @default.
• W2579208110 hasConceptScore W2579208110C2777408456 @default.
• W2579208110 hasConceptScore W2579208110C2777938653 @default.
• W2579208110 hasConceptScore W2579208110C2778461978 @default.
• W2579208110 hasConceptScore W2579208110C31573885 @default.
• W2579208110 hasConceptScore W2579208110C33195913 @default.
• W2579208110 hasConceptScore W2579208110C502942594 @default.
• W2579208110 hasConceptScore W2579208110C55493867 @default.
• W2579208110 hasConceptScore W2579208110C86803240 @default.
• W2579208110 hasConceptScore W2579208110C95444343 @default.
• W2579208110 hasConceptScore W2579208110C98424977 @default.
• W2579208110 hasLocation W25792081101 @default.
• W2579208110 hasOpenAccess W2579208110 @default.
• W2579208110 hasPrimaryLocation W25792081101 @default.
• W2579208110 hasRelatedWork W180295822 @default.
• W2579208110 hasRelatedWork W1965112803 @default.
• W2579208110 hasRelatedWork W1965682168 @default.
• W2579208110 hasRelatedWork W1968667006 @default.
• W2579208110 hasRelatedWork W2041941655 @default.
• W2579208110 hasRelatedWork W2067800681 @default.
• W2579208110 hasRelatedWork W2100824883 @default.
• W2579208110 hasRelatedWork W2102399396 @default.
• W2579208110 hasRelatedWork W2184165313 @default.
• W2579208110 hasRelatedWork W2338693134 @default.
• W2579208110 hasRelatedWork W2530426076 @default.
• W2579208110 hasRelatedWork W2531704280 @default.
• W2579208110 hasRelatedWork W2549484309 @default.
• W2579208110 hasRelatedWork W2554781359 @default.
• W2579208110 hasRelatedWork W2580226070 @default.
• W2579208110 hasRelatedWork W2584106360 @default.
• W2579208110 hasRelatedWork W2588372457 @default.
• W2579208110 hasRelatedWork W2588695861 @default.
• W2579208110 hasRelatedWork W2979456234 @default.
• W2579208110 hasRelatedWork W3177026016 @default.
• W2579208110 isParatext "false" @default.
• W2579208110 isRetracted "false" @default.
• W2579208110 magId "2579208110" @default.
• W2579208110 workType "article" @default.